Skip to main content

CLVR

Stock
Health Care
Drug Manufacturers - Specialty & Generic

Performance overview

CLVR Price
Price Chart

Forward-looking statistics

Beta
0.90
Risk
100.00%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

clever leaves, a colombian company fully-licensed, will become the world’s largest grower with over 10mm+ ft2 of cultivation capacity by 2023, the largest extractor with pharmaceutical grade and gmp certified processing facilities, and the lowest cost operator in cannabis exports. one of the first colombian license holders in the medical cannabis industry. a company positioned to become a leader in the global market with a differentiated business model and strong positioning with regulators, physicians, and other relevant players. developing key capabilities to win in the new space of the medical cannabis industry with a highly experienced and respected team.

Company info

SectorHealth Care
IndustryDrug Manufacturers - Specialty & Generic
Employees288
Market cap$5.7M

Fundamentals

Enterprise value-$4.7M
Revenue$17.4M
Revenue per employee
Profit margin-102.77%
Debt to equity8.62

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$12.63
Dividend per share
Revenue per share$11.11
Avg trading volume (30 day)$0
Avg trading volume (10 day)$0
Put-call ratio

Macro factor sensitivity

Growth
Credit
Liquidity
Inflation
Commodities
Interest Rates

Valuation

Dividend yield0.00%
PEG Ratio-0.00
Price to sales0.00
P/E Ratio-0.00
Enterprise Value to Revenue-0.27
Price to book0.00

Upcoming events

Next earnings dayNovember 10, 2022
Next dividend day
Ex. dividend day

News

Here's Why Akerna And Clever Leaves Stock Are Skyrocketing Today

Shares of several cannabis stocks, including Akerna Corp (NASDAQ: KERN) and Clever Leaves Holdings Inc (NASDAQ: CLVR), are trading sharply higher Thursday afternoon. Shares of cannabis companies at large are trading higher following reports Senate Democrats are planning to introduce a.

Benzinga (July 14, 2022)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free